Under the DARPA Friend or Foe program, Raytheon is developing biosurveillance technology that detects bacterial pathogens as soon as or before they threaten the military and citizens. Current biosurveillance strategies are not effective on undiscovered bacterial strains or on bacteria engineered to evade detection. To overcome this problem, Friend or Foe will characterise bacteria quickly by examining its behaviour.
The screening process begins with collecting and isolating a single bacterium in a tiny cube with a porous membrane. Sensor arrays in the cube make initial measurements on respiration, consumption of specific nutrients and metabolite production. Suspect bacteria is then extracted and exposed to synthetic substances that mimic human tissues to test for pathogenicity.
Aaron Adler, Ph.D. and principal investigator for the Friend or Foe program at Raytheon BBN Technologies, said: “Population growth, global travel, climate change—all of these factors increase the risk of exposure to unfamiliar bacteria.
“Most of those bacteria are harmless or even beneficial, but our goal is to develop a system that lets people know quickly when they are not as a cue to take mitigating action.
“To get a reliable risk assessment, we need to understand not just the bacteria’s genetic makeup, or genotype, but how it functions – its phenotype,” said Adler. “We’re looking at ways to subject the bacteria to a gauntlet of behaviour screenings so we can determine its ability to cause disease.”
If you would like to join our community and read more articles like this then please click here.